Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
304 GBX | +2.70% | +12.18% | +7.42% |
Apr. 05 | Hutchmed to Present New Data at US Cancer Research Conference | MT |
Apr. 05 | HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024 | CI |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 3.52 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.42% | 3.14B | C+ | ||
+24.17% | 562B | B | ||
-6.33% | 358B | C+ | ||
+19.90% | 322B | B- | ||
+7.95% | 297B | C+ | ||
+13.45% | 219B | B+ | ||
+6.04% | 199B | B- | ||
-10.51% | 196B | A+ | ||
-12.26% | 149B | C+ | ||
-6.47% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HCM Stock
- Ratings HUTCHMED (China) Limited